SLDB - Solid Biosciences Inc.
IEX Last Trade
4.295
-0.015 -0.349%
Share volume: 6,726
Last Updated: Fri 27 Dec 2024 08:29:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$4.31
-0.02
-0.35%
Fundamental analysis
10%
Profitability
0%
Dept financing
6%
Liquidity
50%
Performance
10%
Performance
5 Days
6.59%
1 Month
-23.20%
3 Months
-38.10%
6 Months
-23.87%
1 Year
-32.98%
2 Year
-17.08%
Key data
Stock price
$4.30
DAY RANGE
$4.23 - $4.42
52 WEEK RANGE
$4.16 - $15.05
52 WEEK CHANGE
-$28.83
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ilan Ganot
Region: US
Website: solidbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: solidbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles.
Recent news